GSK356278 ( DrugBank: GSK-356278 )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	2

8. Huntington disease

---

Clinical trials : 229 /  Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01573819 (ClinicalTrials.gov)	November 24, 2011	16/2/2012	A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278	A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278	Huntington Disease	Drug: GSK356278;Drug: Placebo	GlaxoSmithKline	NULL	Completed	18 Years	65 Years	All	36	Phase 1	Netherlands
2	NCT01602900 (ClinicalTrials.gov)	November 22, 2011	1/12/2011	Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease	An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)	Huntington Disease	Drug: GSK356278;Drug: Rolipram	GlaxoSmithKline	NULL	Completed	22 Years	55 Years	Male	8	Phase 1	United Kingdom